Objective: To summarize the treatment methods and efficacy of a patient with pure red cell aplasia (PRCA) after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and to accumulate relevant case data. Methods: The clinical treatment and laboratory test data of a patient with PRCA after allo-HSCT in our hospital were retrospectively collected. The therapeutic strategy, monitoring parameters, and treatment outcomes were summarized. Results: Upon suspicion of post-transplant PRCA, the patient was promptly treated with intravenous injection of human immunoglobulin and three sessions of plasma exchange. The titer of blood group antibodies in the patient decreased, and the hemolytic symptoms were relieved. Over one year post-transplantation, the patient exhibited a sustained impairment of erythropoiesis, necessitating continued red blood cell transfusions. After treatment with intravenous daratumumab (400 mg twice weekly for 4 weeks), the pateint's hemoglobin (Hb) and reticulocyte (Ret) levels normalized rapidly, the ABO blood type converted from the recipient to the donor type, and the titer of IgM blood group antibodies returned to normal. The patient was successfully weaned off red blood cell transfusions, indicating the clinical efficacy of the treatment. Conclusion: Daratumumab shows effectiveness in the treatment of refractory PRCA after allo-HSCT in the case. It is essential to monitor Hb, Ret and the titer of blood group antibodies during treatment. Nevertheless, the interference of daratumumab with the titer of blood group antibodies should be considered.

Objective To analyze the clinical characteristics of 1126 cases of malignant lymphoma in our hospital from 2005 to 2009. Methods Age, sex, pathological classification, onset locus and clinical staging of the malignant lymphoma were analyzed and summed up, based on the data of the malignant lymphoma patient information in hospital case database from 2005 to 2009 and excluded the cases as pathology was not sure and the repeated cases. Results A male:female ratio of malignant lymphoma in inpatient was 1.94:1. The majority of Hodgkin lymphoma (HL) manifested in 20-40 years old, mixed cellularity (64.16 %) and nodular sclerosis (29.48%) was most common. The majority of non-Hodgkin lymphoma (NHL) manifested in 50-70 years old, the most common pathological classifications were diffuse large B-cell lymphoma (53.31 %), extranode nasal-type NK/T cell lymphoma (7.35 %), mantle cell lymphoma (6.40 %), B chronic lymphocytic leukemia/small B-cell lymphoma (4.30 %), anaplastic large cell lymphoma (4.09 %), precursor T cell lymphoblastic leukemia/lymphoma (3.88 %), peripheral T cell lymphoma but not otherwise specified (3.46 %), angioimmunoblastic lymphoma(3.04 %), follicular lymphoma(2.94 %), Burkitt lymphoma (2.52 %). The onset locus of both HL and NHL most often involved lymph nodes of the cervical region. Conclusion The gender, age, pathological classification, onset locus and clinical staging of malignant lymphoma were different between HL and NHL.